Biosight Ltd. Revenue and Competitors
Estimated Revenue & Valuation
- Biosight Ltd.'s estimated annual revenue is currently $620k per year.
- Biosight Ltd.'s estimated revenue per employee is $155,000
Employee Data
- Biosight Ltd. has 4 Employees.
- Biosight Ltd. grew their employee count by -33% last year.
Biosight Ltd.'s People
Name | Title | Email/Phone |
---|---|---|
1 | VP Medical Affairs | Reveal Email/Phone |
2 | Clinical Trials Director | Reveal Email/Phone |
Biosight Ltd. Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is Biosight Ltd.?
Biosight is a private Phase 2 clinical stage biotech company developing innovative therapeutics for hematological malignancies and disorders. Biosight's lead product, BST-236 (aspacytarabine), is an innovative proprietary anti-metabolite which addresses unmet medical needs by enabling high-dose chemotherapy with reduced systemic toxicity. BST-236 is currently being investigated as a single agent in a Phase 2b for first-line treatment of acute myeloid leukemia (AML), following completion of a Phase 1/2a study which demonstrated tolerability with promising efficacy in the challenging population of AML patients unfit for standard of care chemotherapy. A Phase 2 study in relapsed/refractory AML and myelodysplastic syndrome (MDS) will be launched in 2020 under a collaboration agreement recently signed with the European cooperative group, GFM.
keywords:N/AN/A
Total Funding
4
Number of Employees
$620k
Revenue (est)
-33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.4M | 14 | 17% | N/A |
#2 | $3.5M | 30 | 114% | N/A |
#3 | $12.7M | 64 | 42% | N/A |
#4 | $10.2M | 71 | 11% | N/A |
#5 | $22M | 74 | 14% | N/A |